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Research into the oxidation of lipoproteins has yielded many new insights into the
pathogenesis of atherosclerosis. However, despite lipoprotein oxidation’s biologically plausible
role in atherogenesis, several studies have reported inconsistent effects of antioxidants on
clinical coronary end points, in sharp contrast with the studies of lipid modification with the
3-hydroxy-3-methylglutaryl coenzyme A inhibitors, or statins. There appears to be little
support for the use of antioxidants in coronary prevention. However, the picture remains
incomplete. What are the limitations of available antioxidant studies and the agents used?
Until the picture can be clarified, lipid modification with strategies proved to reduce the risk
for coronary events, such as statins or dietary changes in the style of the Mediterranean diet,
should be better implemented in clinical practice. (J Am Coll Cardiol 2003;41:1205–10)
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Research into the oxidation of lipoproteins has yielded
many insights into the processes underlying the develop-
ment of atherosclerosis. Steinberg et al. (1) were among the
first to postulate that modified low-density lipoprotein
(LDL) could account for the accumulation of lipid within
macrophages, a critical early step in the formation of the
atherosclerotic plaque. In the early phases, native LDL may
amass in the subendothelial arterial space and may be
minimally oxidized by resident vascular cells through the
activity of such enzymes as 12/15-lipoxygenase (2). In turn,
this minimally modified LDL leads to the production of
chemotactic factors and granulocyte and macrophage
colony-stimulating factors, which enhance recruitment of
circulating monocytes and their differentiation to macro-
phages in the vessel wall. Plaque stability is believed to be
influenced by levels of inflammatory mediators locally,
which may stimulate expression of a number of proteolytic
enzymes that lead to plaque fragility and rupture. These
inflammatory actions encourage further oxidization of
LDL, leading to both structural and functional changes in
the vessel.
Macrophages avidly accumulate LDL particles modified
by oxidation or acetylation through a number of scavenger
receptors, including CD36 and scavenger receptors A-I/II,
leading to the accumulation of foam cells and development
of the atherosclerotic plaque (3,4). At the same time,
oxidized LDL species are directly toxic to vascular cells, and
lead to endothelial injury and dysfunction, disabling, among
other things, the intrinsic antiplatelet effects of this protec-
tive barrier, as well as the generation of nitric oxide, with
deleterious effects on vascular tone and reactivity (2). The
importance of oxidized LDL in atherogenesis has been
further confirmed by the use of specific antibodies to
oxidized LDL, which have been shown to localize to
atherosclerotic lesions in the vessel wall (5). Furthermore,
patients with atherosclerotic disease have elevated levels of
circulating antibodies to modified LDL (6,7).
Up until now, investigations have focused on three main
dietary antioxidant vitamins (beta-carotene, vitamin C, and
vitamin E) and one synthetic antioxidant (probucol). In
hypercholesterolemic New Zealand white rabbits, Bocan et
al. (8) have demonstrated that antioxidant treatment can
lower cholesteryl ester content in thoracic aortic lesions
induced by an atherogenic diet, but has no effect on more
complicated injury-induced iliac-femoral lesions. These
data harmonize with those of earlier studies in the Wa-
tanabe heritable hyperlipidemic rabbit that showed slowed
progression with probucol (9,10).
In the Antioxidant Supplementation in Atherosclerosis
Prevention (ASAP) study, 520 nonsmoking and smoking
men and women were randomized to receive either 91 mg
(136 IU) of d-alpha-tocopherol, 250 mg of slow-release
vitamin C, a combination of these, or placebo for three years
(11). The participants were age 45 to 69 years with serum
cholesterol 193.5 mg/dl (5.0 mmol/l). The primary end
point was atherosclerotic progression defined as the linear
regression slope of the carotid mean intima-media thickness
assessed by ultrasonography. The combination regimen was
associated with significantly less progression in treated men
(mean increase in intima-media thickness of 0.020 mm/year
in the placebo group vs. 0.011 in the vitamin combination
group, p  0.008); no significant benefit was observed in
treated women. The authors concluded that combined
supplementation of vitamins E and C in reasonable doses
slowed common carotid atherosclerosis.
Despite a plausible biological role for lipoprotein oxida-
tion in disease progression and some evidence of angio-
graphic benefit, the clinical cardiovascular effects of antiox-
idant treatments have not been satisfactorily demonstrated
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(12). What may account for these disappointing results, and
how does the future of antioxidant therapy look in light of
the growing predominance of other cardiovascular risk
reduction strategies with better results, such as the
3-hydroxy-3-methylglutaryl coenzyme A inhibitors, or st-
atins? This review will evaluate briefly the evidence in favor
of and against antioxidant treatment with current agents
and discuss these in the context of the statin trials.
ANTIOXIDANT THERAPY IN
CORONARY ARTERY DISEASE (CAD) PREVENTION
Observational data. Observational studies have looked at
the relationship between antioxidant vitamin intake and
cardiovascular events, generally using assessments of intakes
based upon dietary recall. In the Nurses’ Health study,
which included over 87,000 participants (13), coronary
events and vitamin E intake were inversely correlated. On
the other hand, among almost 40,000 male participants in
the Health Professionals’ Follow-up study (14), while beta-
carotene intake was associated with reduced coronary risk in
the whole cohort, vitamin E was associated with reduced
risk only in the subgroup who were smokers. Among almost
12,000 subjects in the second National Health and Nutri-
tional Examination Survey (15), there was an inverse rela-
tion between vitamin C intake and coronary risk. Finally, in
a study in over 11,000 elderly patients (16), fewer coronary
events were seen in subjects consuming dietary supplements
of vitamin E than in those without supplementation. A
Dutch study of 4,802 participants, age 55 to 95 years, with
no history of myocardial infarction (MI) reported that the
greatest risk for MI was associated with the lowest intake of
beta-carotene; no association between vitamins E and C
with MI was found (17).
Interventional data. Interventional trials have examined
antioxidant vitamin therapy compared with placebo in a
randomized, double-blind fashion, in subjects at varying
degrees of cardiovascular risk. The large Finnish Alpha-
Tocopherol-Beta-Carotene (ATBC) cancer prevention
study, although designed to study the effects of vitamin E
and beta-carotene on lung cancer risk in male smokers age
50 to 69 years, also evaluated effects on cardiovascular risk;
no cardiovascular benefit was found in the overall cohort.
An analysis excluding the 1,862 men with a reported history
of MI in ATBC affirmed this negative finding: a small dose
of vitamin E in primary prevention had only a marginal and
statistically insignificant effect on fatal CAD events and
none on nonfatal MI (18). In the Physicians’ Health study,
among 22,000 U.S. physicians (19), there was no effect of
beta-carotene use on coronary events.
The potential benefits of probucol in atherosclerosis have
been evaluated both in animal models and in clinical trials
that have not made a consistent case in favor of this
synthetic antioxidant. In the Probucol Quantitative Regres-
sion Swedish trial, 303 hypercholesterolemic patients with
femoral atherosclerosis were treated for three years with
probucol (0.5 g twice a day) added to diet plus cholestyra-
mine (8 g twice a day), to see whether probucol could retard
progression or induce regression of atherosclerosis, as as-
sessed by change in lumen volume on quantitative angiog-
raphy in a 20-cm segment of the femoral artery. Although
probucol lowered low-density lipoprotein cholesterol
(LDL-C) by 12%, no statistically significant benefit on
atherosclerotic progression was observed, a null finding
perhaps related to the significant reductions in protective
high-density lipoprotein cholesterol (HDL-C) induced by
probucol (20).
More recently, some groups have studied the effect of
probucol and antioxidant vitamins on restenosis after an-
gioplasty. In the MultiVitamins and Probucol (MVP) study,
317 patients were randomized to receive one of the follow-
ing: placebo, probucol (500 mg), multivitamin cocktail
(beta-carotene, 30,000 IU; vitamin C, 500 mg; vitamin E,
700 IU), or both probucol and multivitamins given twice
daily (21). Probucol monotherapy was associated with a
restenosis rate per segment of 20.7%, while the rate in those
treated with the combined regimen was 28.9% and in those
on placebo 38.9% (p  0.009 for probucol vs. no probucol).
Probucol appeared to exert its antirestenotic effects by
improving vascular remodeling after angioplasty (22). Given
the size of both trials, no definitive conclusion about
probucol’s effects on cardiovascular event rates can be made.
Other trials have reported positive results. The Cam-
bridge Heart AntiOxidant Study (CHAOS), conducted in
the United Kingdom in 2,000 men and women with
angiographic evidence of CAD, showed a benefit of natu-
rally occurring antioxidant therapy (23). Participants were
randomized to either placebo or vitamin E at a substantial
dose of 400 to 800 IU per day. After a median follow-up
period of 17 months, there was a 47% reduction in cardio-
vascular death and nonfatal MI and a 77% reduction in
nonfatal MI among the patients on the antioxidant.
The Secondary Prevention with Antioxidants of Cardio-
vascular disease in End-stage renal disease (SPACE) study
suggested that vitamin E, 800 IU/day, delivered as natural
Abbreviations and Acronyms
ASAP  Antioxidant Supplementation in
Atherosclerosis Prevention study
ATBC  Alpha-Tocopherol-Beta-Carotene cancer
prevention study
CAD  coronary artery disease
CHAOS  Cambridge Heart AntiOxidant Study
HATS  High-density lipoprotein Atherosclerosis
Treatment Study
HDL-C  high-density lipoprotein cholesterol
LDL  low-density lipoprotein
LDL-C  low-density lipoprotein cholesterol
MI  myocardial infarction
MVP  MultiVitamins and Probucol study
SPACE  Secondary Prevention with Antioxidants of
Cardiovascular disease in End-stage renal
disease study
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alpha-tocopherol, decreased the relative risk for a composite
primary end point of MI, ischemic stroke, peripheral vas-
cular disease, and unstable angina by 54% (p  0.014) (24).
The study was conducted in a small sample (N  196) of
patients on hemodialysis with a history of cardiovascular
disease, an exceptionally high-risk group, followed for a
median 519 days. The annual placebo event rate for definite
fatal and nonfatal MI in the SPACE trial was 12.3% per
year (17.2% over 519 days), much higher than that in
CHAOS (Table 1). These findings complement those from
a double-blind prospective study of 40 cardiac transplant
patients treated for one year either with placebo or with a
cocktail of vitamin C, 500 mg, plus vitamin E, 400 IU, each
given twice daily (25). In these transplant patients, for
whom accelerated atherogenesis is a common risk, those
who had antioxidant treatment had less coronary progres-
sion compared with those who did not receive the vitamins.
The change in the intimal index was 0.8% versus 8%,
respectively (p  0.008). Therefore, additional clinical trials
are needed to clarify whether the baseline risk of the patient
and the type and dosage of antioxidant used are key
determinants of the efficacy of antioxidant therapy.
ANTIOXIDANT PROPERTIES OF STATIN THERAPY
The equivocal interventional data with antioxidant treat-
ment are in sharp contrast with the clinical experience with
lipid modification, in which several large, prospective trials
have reported significant event reductions. Based on six
landmark clinical trials, the statins are widely recognized to
reduce the risks for CAD, and to improve survival and
decrease recurrence of clinical cardiovascular events in CAD
patients (26–32). Their primary mechanism of benefit
probably relates to their ability to lower levels of LDL-C by
enhancing hepatic receptor-mediated clearance of apoli-
poprotein-B–containing particles. However, a number of
secondary mechanisms of benefit have been postulated, and
some of these have been observed experimentally. These
so-called pleiotropic effects include direct anti-inflammatory
actions, nitric-oxide–mediated improvement in vascular
function, inhibition of cell proliferation, “stabilization” of
atherosclerotic plaques, and antioxidant effects (33).
The capacity of statins to prevent lipoprotein oxidation is
relevant to this discussion, although the proportion of the
clinical benefits associated with these drugs due to this effect
remains unknown. In vitro human and animal data suggest
that fluvastatin may exert antioxidant effects that protect
against lipid peroxidation (34,35). Simvastatin inhibits
LDL oxidation by activated human monocyte-derived mac-
rophages, and the metabolites of atorvastatin have been
shown to have potent antioxidant effects (36,37). A recent
study reported that neonatal rat cardiac myocytes incubated
with simvastatin and treated with angiotensin II displayed
reduced evidence of hypertrophy compared with myocytes
that were not incubated with simvastatin. This effect may be
associated with an antioxidant mechanism involving statin-
related inhibition of Rac1, a small G protein of the Rho
family (38).
TRIALS OF THERAPIES IN
COMBINATION WITH ANTIOXIDANTS
The Heart Outcomes Protection Evaluation (HOPE) trial
compared ramipril versus placebo in subjects who were at
elevated risk for heart disease, but who were without an
established indication for angiotensin-converting enzyme
Table 1. Selected Clinical Trials of Natural Antioxidant Therapies on Atherosclerotic Events*
Trial N
Antioxidant
Dosage
Rx
Event† Rate
Placebo
Event† Rate RR
Vitamin E
ATBC‡ 27,271 50 mg (synthetic) 7.6% 7.8% 4%
CHAOS 2,002 400 or 800 IU (natural) 4.0% 6.6% 47%
SPACE§ 196 800 IU (natural) 5.2% 17.2% 70%
GISSI 11,324 300 mg (synthetic) 8.0% 8.0% 0
HOPE§ 9,541 400 IU (natural) 11.2% 11.0% 2%
Beta-Carotene
ATBC 27,271 20 mg (synthetic) 8.0% 7.8% 1%
Vitamin Cocktails
ATBC 27,271 50 mg vit. E, 20 mg beta-carotene 7.5% 7.8% 4%
Heart Protection
Study
20,536 600 mg vit. E, 250 mg vit. C,
20 mg beta-carotene
10.4% 10.2% 2%
*Defined as fatal cardiovascular or coronary artery disease or nonfatal myocardial infarction; †crude event rate as calculated by
the number of events divided by the size of the treatment group; ‡primary prevention analysis, excluding 1,862 men with a
history of myocardial infarction; §myocardial infarction only. Bold highlighting of trial name denotes statistically significant
change in relative risk (p  0.05).
ATBC  Alpha-Tocopherol-Beta-Carotene Cancer Prevention study; CHAOS  Cambridge Heart AntiOxidant study;
GISSI  Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico-prevenzione study; HATS  High-density
lipoprotein Atherosclerosis Treatment Study; HOPE  Heart Outcomes Protection Evaluation trial; Rx  treated; SPACE 
Secondary Prevention with Antioxidants of Cardiovascular disease in End-stage renal disease; vit.  vitamin; RR  change
in relative risk.
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inhibitor therapy (39). There were also groups randomized
to vitamin E alone, and to vitamin E plus ramipril. No
benefit of vitamin E was seen in either group (40).
The Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto miocardico prevenzione trial (GISSI) evaluated
the effect of 3.5 years of treatment with n-3 polyunsaturated
fatty acids (fish oil supplement, 1 g daily) and vitamin E
(200 mg/day), either alone or in combination, versus pla-
cebo, in the management of 11,324 recent survivors of MI
(41). While fish oil supplementation reduced the relative
cardiovascular risk by 10% with only minimal lipid changes,
vitamin E produced no benefit. The combination of the two
did not lessen the benefit compared with fish oil alone,
suggesting that vitamin E did not mitigate the effect.
In contrast, the High-density lipoprotein Atherosclerosis
Treatment Study (HATS) (42), a joint U.S.-Canadian trial
that investigated the effects of simvastatin, niacin, and
antioxidant vitamins, suggested a potential dilution of ben-
efit. The HATS included 160 patients with angiographi-
cally demonstrated CAD, normal LDL-C levels, and low
HDL-C levels (35 mg/dl [0.9 mmol/l]). The primary
angiographic end point was quantitative change at the end
of 36 months of therapy in a 2  2 comparison of: 1)
simvastatin (10 to 20 mg)/niacin (2 to 4 g); 2) that regimen
 antioxidant vitamins; 3) antioxidant vitamins alone; and
4) placebo. The antioxidant cocktail used included: 800 IU
of vitamin E, as d-alpha-tocopherol; 1,000 mg of vitamin
C; 100 g of selenium; and 25 mg of natural beta-carotene.
The average stenosis progressed by 3.9% in the placebo
group versus 0.7% in the group receiving both the cocktail
and niacin/simvastatin (p  0.004 vs. placebo), while
regression of 0.4% was seen in the group treated with
simvastatin/niacin without antioxidants (p  0.001 vs.
placebo). Therefore, patients who got both therapies ap-
peared to experience less angiographic benefit than those
who received simvastatin/niacin alone (p 0.02). Given the
small size of this study, additional investigations will be
needed before a more serious caution against their combined
use is warranted.
The Heart Protection Study evaluated the effects of statin
therapy and antioxidant vitamins in 20,536 patients at high
risk of coronary events with a wide range of baseline serum
cholesterol levels (31,32). Subjects in the trial were at high
risk for an ischemic event, based upon existing coronary
disease, other vascular disease, diabetes, or hypertension,
and were treated for a median of five years with simvastatin
40 mg/day or placebo, along with, in a 2  2 design, an
encapsulated antioxidant “cocktail” (vitamin E, 600 mg;
vitamin C, 250 mg; beta-carotene, 20 mg), or matching
placebo. Although simvastatin significantly reduced the
risks for coronary morbidity and mortality, there was no
evidence of either benefit or harm from antioxidant mono-
therapy, nor did concomitant antioxidants mitigate the
benefits of statin therapy.
DISCUSSION
While the use of antioxidants to prevent CAD has not been
satisfactorily demonstrated, Steinberg and Witztum (43)
have recently argued persuasively in favor of continued
research, citing a number of limitations and unanswered
questions related to earlier attempts to evaluate the oxida-
tion hypothesis in clinical trials. For example, because it is
not certain exactly where and how LDL gets oxidized in
vivo, pharmacokinetic differences between available antioxi-
dants may be especially germane to the findings seen thus
far (e.g., beta-carotene given in large doses does not appear
to protect LDL from oxidation ex vivo; vitamin C is
transported in the aqueous phase, while vitamin E takes up
residence in lipoproteins) (12). Other reasons may explain
why antioxidant intervention trials have not been so suc-
cessful in humans. The agents studied may not be potent
enough, and the doses used may be too low. What kinds of
potent novel antioxidants will need to be developed?
The patients studied in trials have had advanced degrees
of cardiovascular disease; prevention of oxidative modifica-
tion may be more important in earlier stages of lesion
development, but less effective for established atherosclero-
sis. The rate of oxidation in humans also may be less than in
other experimental animal models, accounting for the dis-
cordance between animal and human trials. The lack of
benefit in the high-risk Heart Protection Study cohort
suggests that high risk alone cannot be the basis for
initiating antioxidants (32). As seen in the ASAP study
(11), the MVP study (21), the SPACE study (24), and Fang
et al. (25), the patient profile may be an important consid-
eration in the efficacy of antioxidant therapy, especially in
those groups for whom the mechanical processes underlying
atherosclerosis may be accelerated. Aggressive antioxidant
supplementation may prove a specialized approach for
cardiovascular prevention in certain kinds of patients.
A small study showed that pretreatment with vitamin C
(1 g) and vitamin E (800 IU) appeared to inhibit postpran-
dial endothelial dysfunction after a high-fat meal, as as-
sessed by brachial ultrasonography (44). There is some
controversy whether antioxidants taken as diet supplements
yield qualitative differences from those consumed in a diet
that includes antioxidant-rich foods. In a combined analysis
from the Nurses’ Health study and the Health Professionals’
Follow-up study, every one-serving/day increase in con-
sumption of leafy green vegetables and vitamin C-rich fruits
and vegetables was associated with a 4% decrease in relative
risk for coronary disease (45). Dietary plant-derived fla-
vonoids, as found in grape juice, wine, and soy products,
have also gained attention for their antioxidant properties,
based on observational trials that associate intake of these
substances with cardiovascular protection (46). The pro-
spective single-blinded Lyon Diet Heart study reported a
72% relative risk reduction in recurrent coronary events (p
0.0001) in heart attack survivors on a Mediterranean diet
compared with a prudent “Western”-type diet (47). The
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composition of the Mediterranean diet favors foods with
antioxidant potential, but the overall diet includes other
cardioprotective characteristics, such as reduced saturated
fats, greater use of unsaturated fats like olive oil, and fish
and plants high in concentrations of alpha-linolenic acid
(48). It may be the synergy of this overall more healthful
eating pattern that accounts for benefits observed than any
individual effect of the diet.
In patients with coronary disease, lipid-altering therapy
with statins should be a cornerstone of pharmacologic
treatment, with a priority of getting LDL-C levels to
recommended targets. Both groups receiving simvastatin in
HATS had mean final LDL-C levels below 80 mg/dl (2.07
mmol/l), and the treatments were well-tolerated. Simvasta-
tin/niacin therapy was associated with a mean increase in
HDL-C of about 30%, suggesting that combined therapy
may be appropriate when HDL-C levels are low.
In conclusion, we cannot discount the oxidation hypoth-
esis in human atherosclerosis, and experiments to date have
only illustrated the difficulties in testing this complex issue.
While the search continues for insights and potential
therapies related to lipoprotein oxidation, better use of the
therapies already available is needed to address unfavorable
risk factor profiles and to reduce cardiovascular risk.
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